The 2020 Narcolepsy pipeline report presents a comprehensive overview of the research and development of Narcolepsy drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: One drug in Research phase, four drugs in Pre-clinical phase, four drugs in Phase 1, five drugs in Phase 2, three drugs in Phase 3 and one drug in pre-registration phase.
As of February 2020, the Narcolepsy pipeline remains robust with 19 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Narcolepsy treatment. Diverse types of targeted therapies are being explored through clinical trials including Adrenergic receptor agonists; Adrenergic uptake inhibitors; Dopamine uptake inhibitors; GABA A receptor antagonist; GABA B receptor agonists; Histamine H3 receptor antagonists; Orexin receptor type 1 agonists; Orexin receptor type 2 agonists; Prostaglandin D2 receptor antagonists; TAAR1 agonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Narcolepsy drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
Publisher Expertise
The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
Scope:
Narcolepsy pipeline companies included in the report are: Avadel Pharmaceuticals Plc, Axsome Therapeutics Inc, Balance Therapeutics Inc, Bioprojet SCR, F. Hoffmann-La Roche Ltd, Inexia, Jazz Pharmaceuticals Plc, NLS Pharma Group, NLS Pharmaceutics Ltd, Ono Pharmaceutical Co Ltd, Seelos Therapeutics Inc, SK Biopharmaceuticals Co Ltd, Suven Neurosciences Inc, Takeda Pharmaceutical Co Ltd, Theranexus SAS, Vallon Pharmaceuticals Inc , XW Laboratories Inc.
Narcolepsy pipeline drugs profiled in the report include: FT218 (sodium oxybate), BTD-001 (Pentylenetetrazole), pitolisant, RO5256390, mazindol, JZP-258, JZP-507, ONO-4127Na, OX1 and OX2 agonists for Narcolepsy, SLS-010, solriamfetol, SUVN-G3031, TAK-925, THN102 (flecainide and modafinil), XW-10172, XWL-008, dextroamphetamine, mazindol , reboxetine.
As of February 2020, the Narcolepsy pipeline remains robust with 19 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Narcolepsy treatment. Diverse types of targeted therapies are being explored through clinical trials including Adrenergic receptor agonists; Adrenergic uptake inhibitors; Dopamine uptake inhibitors; GABA A receptor antagonist; GABA B receptor agonists; Histamine H3 receptor antagonists; Orexin receptor type 1 agonists; Orexin receptor type 2 agonists; Prostaglandin D2 receptor antagonists; TAAR1 agonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Narcolepsy drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
Publisher Expertise
The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
Scope:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Narcolepsy development
- Narcolepsy pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Narcolepsy pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Narcolepsy pipeline candidates included
- Business overview and snapshot of all companies involved in Narcolepsy pipeline are included
- Latest market and pipeline developments are provided in the report
Narcolepsy pipeline companies included in the report are: Avadel Pharmaceuticals Plc, Axsome Therapeutics Inc, Balance Therapeutics Inc, Bioprojet SCR, F. Hoffmann-La Roche Ltd, Inexia, Jazz Pharmaceuticals Plc, NLS Pharma Group, NLS Pharmaceutics Ltd, Ono Pharmaceutical Co Ltd, Seelos Therapeutics Inc, SK Biopharmaceuticals Co Ltd, Suven Neurosciences Inc, Takeda Pharmaceutical Co Ltd, Theranexus SAS, Vallon Pharmaceuticals Inc , XW Laboratories Inc.
Narcolepsy pipeline drugs profiled in the report include: FT218 (sodium oxybate), BTD-001 (Pentylenetetrazole), pitolisant, RO5256390, mazindol, JZP-258, JZP-507, ONO-4127Na, OX1 and OX2 agonists for Narcolepsy, SLS-010, solriamfetol, SUVN-G3031, TAK-925, THN102 (flecainide and modafinil), XW-10172, XWL-008, dextroamphetamine, mazindol , reboxetine.
Table of Contents
1. Table of Contents
2. Executive Summary
3. Companies Active in Pipeline Development
4. Active Pipeline Drug Details, 2020
6. Appendix
Companies Mentioned
- Avadel Pharmaceuticals Plc
- Axsome Therapeutics Inc
- Balance Therapeutics Inc
- Bioprojet SCR
- F. Hoffmann-La Roche Ltd
- Inexia
- Jazz Pharmaceuticals Plc
- NLS Pharma Group
- NLS Pharmaceutics Ltd
- Ono Pharmaceutical Co Ltd
- Seelos Therapeutics Inc
- SK Biopharmaceuticals Co Ltd
- Suven Neurosciences Inc
- Takeda Pharmaceutical Co Ltd
- Theranexus SAS
- Vallon Pharmaceuticals Inc
- XW Laboratories Inc
